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Functional expression of a glutamate-gated chloride channel (GLC-
3) from adult Brugia malayi. 
 
Bukunmi Akanji, Melanie Abongwa, Mark McHugh, Richard J. Martin & Alan P. Robertson 
Department of Biomedical Science, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, USA. 
Abstract 
 
Parasitic worms are causative agents for six highly prevalent neglected tropical diseases of humans 
which include ascariasis, lymphatic filariasis, schistosomiasis, trichuriasis, hookworm infection, 
and onchocerciasis that affect a high percentage of the world’s population. Resistance to available 
anthelminthic drugs especially for the benzimidazole anthelmintic agents (e.g., albendazole and 
mebendazole) and ivermectin is a serious concern (this is a real problem for veterinary medicine 
and a growing concern in human medicine). Previous studies involving ivermectin have shown 
that it has a limited action against adult filarial worms. Here, we describe the functional expression 
of a glutamate-gated chloride channel (GLC-3) from adult Brugia malayi, a filarial parasite. We 
expressed GLC-3 in Xenopus laevis oocytes and used two-electrode voltage-clamp 
electrophysiology to study the resulting ion channel. Application of various receptor agonists (1 
mM): L-aspartate, glycine, γ-aminobutyric acid (GABA), α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) and N-methyl-D-aspartate (NMDA) failed to activate the GLC-
3 receptor. Application of 1mM L-glutamate and ibotenate produced robust inward currents. 
Further experiments revealed that GLC-3 is a glutamate-gated channel with an EC50 of 64.8  4.01 
µM and a Hill coefficient of 2.56  0.46 µM. We recorded the responses to 300 µM L-glutamate 
over a range of holding potentials (-80 to +20 mV) and constructed a current-voltage plot. The 
current-voltage relationship revealed a reversal potential (Erev) of -35.3  3.2 mV indicating the 
GLC-3 channel is selective for chloride ions. The GluCl channel antagonists picrotoxin and 
fipronil had negligible inhibitory effects on the L-glutamate responses. We investigated the 
ivermectin effects on the GLC-3 receptor which reveals ivermectin to be an agonist with an EC50 
of 3.6 nM (pEC50 = -2.4 ± 0.4). Interestingly, we also observed that Ivermectin has an inhibitory 
effect on the GLC-3 glutamate response at very low concentrations, IC50 = 73 pM (pIC50 = -4.1 ± 
11.4). This is in stark contrast to the previously reported positive allosteric (PAM) effects of 
ivermectin on many invertebrate GluCls. 
 
Keywords: Glutamate-gated chloride channel; Brugia malayi; Ivermectin, Picrotoxin; Fipronil; 
Two-electrode voltage-clamp electrophysiology. 
Abbreviations: GluCls, glutamate-gated chloride channels; ML, macrocyclic lactone; LGICs, 
ligand-gated ion channels; Bma, Brugia malayi; I-V, current-voltage; Erev, reversal potential; PCR, 
polymerase chain reaction; NCBI, National Center for Biotechnology Information; NEB, New 
England BioLabs; GABAA, γ-aminobutyric acid type A; AMPA, α-amino-3-hydroxy-5-methyl-4-
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isoxazolepropionic acid; NMDA, N-methyl-D-aspartate; IVM, ivermectin; PTX, picrotoxin; FIP, 
fipronil; DMSO, dimethyl sulfoxide. 
 
 
Introduction 
 
Parasitic nematodes are responsible for many 
diseases in humans and animals as well as 
infecting crops affecting global economic 
growth and production. These nematodes are 
the causative agents for highly prevalent 
neglected tropical diseases in tropical and 
subtropical regions of the world (Garcia, 
2007). Lymphatic filariasis causes a high 
burden of disease, with more than 120 
million individuals globally infected (NIAID, 
2007).  Filarial nematodes (e.g., Brugia 
malayi, Brugia timori, and Wuchereria 
bancrofti) are predominantly responsible for 
lymphatic filariasis (Rick et al., 2011). The 
filarial worms are transmitted through the 
bite of insect vectors Such as members 
of Anopheles, Culex, Aedes, Mansonia, and 
Ochlerotatus genera of mosquitoes (Bobbi, 
2015). 
 
In sub Saharan countries such as Burkina 
Faso, Niger, Nigeria, Ghana, Togo, and 
Uganda, efforts to control neglected tropical 
diseases are in progress. However, there are 
challenges to eradicating these diseases 
which include proper assessment of safety, 
compatibility, and amenability (Hotez et. al., 
2007). The World Health Organization 
(WHO) launched the Global Program to 
Eliminate Lymphatic Filariasis (GPELF) in 
the year 2000, with the aim to eliminate 
lymphatic filariasis as a public health 
problem by 2020. While, the GPELF also 
ensures morbidity management and disability 
prevention (MMDP), mass drug 
administration (MDA) has been effective for  
 
 
 
control of infection such as the use of 
Diethylcarbamazine and albendazole for 
Lymphatic filariasis. 
 
Glutamate-gated chloride channels (GluCls) 
are members of the Cys-loop ligand-gated 
ion channel family present in neurons and 
myocytes. Glutamate-gated chloride 
channels have been described to be 
conserved in invertebrate species. They play 
major roles in invertebrate nervous systems, 
by controlling locomotion, regulating feeding 
and mediating sensory inputs. Although 
GluCls are only found in invertebrates 
(Cleland, 1996), they are closely related to 
vertebrate γ-aminobutyric acid-A GABAA 
and glycine receptors (Vassilatis et. al., 
1997). GluCls are targets for the 
avermectin/milbemycin (A/M) family of 
anthelmintics such as ivermectin that cause 
paralysis of pharyngeal muscles in 
gastrointestinal nematodes. Ivermectin is also 
useful for filarial control programs because 
of its activity against microfilariae that often 
cause ocular disease and severe dermatitis 
(Ben et. al., 2014). The invertebrate GABA-
gated chloride channels are also targeted by 
insecticides such as the phenylpyrazole, 
fipronil, providing further evidence of the 
importance of the ligand-gated anion channel 
superfamily in pest control (Lucy et. al., 
2001). GluCls are also targets of the 
avermectin/milbemycin (A/M) family as 
endectocides and insecticides (Cully et al., 
1994; Dent et al., 2000).  
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Adult B. malayi are mainly found in the 
lymphatic vessels of humans, causing 
lymphatic filariasis, sometimes characterized 
with swelling of the limbs (elephantiasis). B. 
malayi can be maintained in the laboratory, 
unlike the more common cause of lymphatic 
filariasis, Wuchereria bancrofti, which 
makes the former a suitable model parasite 
(Verma et. al., 2017). 
Most studies involving Ivermectin have 
shown that it has a limited action against 
adult filarial worms and is not an effective 
adulticide in vivo. The objective of this study 
was to examine the functional expression of 
a GluCl (Bma-GLC-3) from adult B. malayi. 
We directly measured the effects of IVM on 
application of L-glutamate to oocytes 
expressing the GLC-3 receptor.  
 
Materials and Methods 
Cloning of B. malayi glc-3 
 
Total RNA from 3 adult female B. malayi 
was extracted using TRIzol ReagentTM 
(InvitrogenTM, Carlsbad, CA, USA) and 
cDNA was synthesized from the total RNA 
using oligo(dT)12 – 18 as primers. Reagents 
used were from the SuperScriptTM IV 
VILOTM Master Mix (InvitrogenTM, 
Carlsbad, CA, USA). cDNA was used as 
template for PCR full length amplification of 
the B. malayi glc-3 sequence (WormBase ID: 
8050) using Phusion® High Fidelity DNA 
Polymerase (Thermo Scientific, Carlsbad, 
CA, USA) at an annealing temperature of 
55°C and for 40 PCR cycles. Using the online 
NEB Tm calculator, specific primers were 
designed and used for PCR amplification of 
Bm-glc-3 (forward primer: 5’-
AAAgaattcCCACCATGCTTCTTCCGC
ACTACG -3’; reverse primer:5’- 
AAAgggcccTTATGTTGGTCTTGATA
CCGG -3’). Restriction enzymeEcoRI 
(gaattc) and ApaI (gggccc) sites were 
respectively added to the 5’ end of the 
forward and reverse primers to enable sub-
cloning into the pTB 207 expression vector. 
For optimal translation of Bma-glc-3, the 
Kozac motif (CCACC) was also added to the 
start of the forward primer. The resulting 
PCR products were digested with restriction 
enzymes EcoRI and ApaI and gel-purified 
using the NucleoSpin® Gel and PCR Clean‐
up kit (Macherey‐Nagel Inc., Bethlehem, PA, 
USA). The purified PCR products were then 
ligated into the pTB207 expression vector 
which was linearized by EcoRI and ApaI 
restriction enzymes. The final constructs 
were sequenced with pTB207 vector primers 
(forward, T7) and (reverse, SP6) and only 
positive clones were used for cRNA 
synthesis. 
 
cRNA Preparation for oocyte injection 
cDNA/pTB207 plasmids were linearized 
using PstI at the 3’ end of the untranslated 
Xenopus β-globulin region. The linearized 
plasmids were purified using the 
NucleoSpin® Gel and PCR Clean‐up kit 
(Macherey‐Nagel Inc., Bethlehem, PA, 
USA) and served as template for cRNA 
transcription using the T7 RNA polymerase 
and a mMessage mMachine in vitro 
transcription kit (Invitrogen TM, Carlsbad, 
CA, USA). The quality of cRNA was 
checked on a 1% agarose gel and quantified 
by absorption microscopy. cRNA was stored 
at – 80oC until needed for microinjection into 
Xenopus oocytes. 
Oocyte preparation and microinjection 
De-folliculated Xenopus laevis oocytes 
obtained from Ecocyte Bioscience (Austin, 
TX, USA) were injected with 15-60 ng of 
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Bma–glc-3 cRNA in 50 nl in nuclease-free 
water as previously described (Abongwa et 
al., 2016). Briefly, each oocyte was injected 
at the animal pole cytoplasmicaly with cRNA 
using a nanoject II microinjector (Drummond 
Scientific, PA, USA). Injected oocytes were 
incubated in sterile oocyte incubation 
solution (88 mM NaCl, 1 mM KCl, 0.4 mM 
CaCl2·2H2O, 0.33 mM Ca(NO3)2, 0.8 mM 
MgSO4, 5 mM Tris-HCl, 2.4 mM NaHCO3, 
2.5 mM Na pyruvate, 100 U/mL penicillin, 
100 μg/mL streptomycin, pH 7.4), one 
oocyte per well of 96-well culture plates. The 
oocytes were then incubated at 19oC for 2-7 
days to allow proper receptor expression with 
replacement of incubation solution at 24 
hours intervals. 
Chemicals 
L - glutamate, L - aspartate, glycine, γ - 
aminobutyric acid (GABA), α - amino - 3 - 
hydroxy - 5 - methyl - 4 - isoxazolepropionic 
acid (AMPA), N - methyl - D - aspartate 
(NMDA), ivermectin, picrotoxin and fipronil 
were purchased from Sigma - Aldrich (St 
Louis, MO, USA). Ibotenic acid (Ibotenate), 
kainic acid (kainate) and quisqualic acid 
(quisqualate) were obtained from Tocris 
Bioscience (Bio - Techne Corporation, 
Minneapolis, MN, USA). All chemicals were 
dissolved in recording solution (100 mM 
NaCl, 2.5 mM KCl, 1 mM CaCl2.2H2O and 
5 mM HEPES, pH 7.3), except ivermectin, 
picrotoxin and fipronil which were dissolved 
in DMSO. 
Electrophysiology recordings 
Membrane current measurements of oocytes 
expressing Bma–glc-3 were made using the 
two-electrode voltage-clamp 
electrophysiology technique as described by 
Abongwa et al. (2016). Microelectrodes were 
pulled using a Flaming/Brown horizontal 
electrode puller (Model P - 97; Sutter 
Instruments, Novato, CA, USA). The pulled 
microelectrodes were filled with 3 M KCl, 
and their tips were cautiously broken with 
tissue paper to attain a resistance of 2-5 MΩ 
in recording solution. Each oocyte was 
positioned in an oocyte recording chamber 
and impaled with two microelectrodes. An 
Axoclamp 2B amplifier (Warner 
Instruments, Hamdem, CT, USA) was used 
for recording oocytes voltage-clamped at –80 
mV except when otherwise stated. Non-
injected oocytes served as control for these 
experiments. Data were stored on a computer 
using Clampex 9.2 (Molecular Devices, 
Sunnyvale, CA, USA). 
Drug applications 
L - glutamate, L - aspartate, glycine, GABA, 
AMPA, NMDA, ibotenate, kainate and 
quisqualate were tested as agonists at an 
initial concentration of 1 mM. Each chemical 
was applied for 5 s, after that, a wash period 
of 2 mins with recording solution in between 
the drug applications was allowed, to reduce 
the effects of desensitization. A dose-
response relationship for L-glutamate was 
generated by first challenging the oocytes 
with a control application of 1 mM L-
glutamate for 5 s, followed by increasing 
concentrations of L - glutamate (3 µM to 1 
mM), and 2 mins wash with recording 
solution in between applications. 
GLC-3 responses to 5 s applications of 300 
M L-glutamate were recorded over a range 
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of holding potentials (–80 to +20 mV). The 
oocyte was held at a membrane potential of –
80 mV and 300 M glutamate was applied 
for 5 s. This was followed by a 2-3 mins wash 
with recording solution after which the 
glutamate application was repeated at –60, –
40, –20, 0 and +20 mV. Again, a 3 mins wash 
with recording solution was allowed between 
drug applications. 
For studies on the antagonists’ fipronil and 
picrotoxin, oocytes were analyzed in 
different antagonist test concentrations. 
Briefly, 300 M L-glutamate was applied 
followed by a 2-minute wash, antagonist (0.3 
µM-100 µM) was applied for 30 seconds 
before 300 µM L-glutamate was applied 
again (5 s). After a 2-minute wash period the 
process was repeated with a higher antagonist 
concentration. The amplitude of the response 
to co-application of antagonist and L-
glutamate was normalized to the values 
obtained in the presence of 300M L-
glutamate in physiological saline. 
Concentration-response relationships for 
ivermectin, were performed by first 
challenging the oocytes with L-glutamate at 
concentrations of 10M, 100M and 1mM 
for 5 s, ivermectin (1 ρM – 0.1 μM) was then 
constantly perfused for 5 minutes before re-
probing with the 3 glutamate concentrations. 
We measured the amplitude of the ivermectin 
induced currents at various concentrations to 
determine the dose-response relationship for 
ivermectin as an activator of the receptor. We 
also compared the glutamate responses in the 
presence of ivermectin with controls to 
determine the dose-response relationship for 
ivermectin as an inhibitor of glutamate 
responses.  
Data analysis 
We used Clampfit 10.2 (Molecular Devices, 
CA, and USA) and GraphPad Prism 5.0 
(Graphpad Software Inc., CA, USA) to 
analyze acquired data observed and results 
were presented as mean ± s.e.m. For agonist 
rank order potency experiments, peak current 
responses to agonist application were 
normalized to a 1 mM L - glutamate 
response. However, for fipronil and 
picrotoxin antagonist experiments, peak 
currents evoked following drug applications 
were normalized to a 300 M L - glutamate 
application. 
Results 
Sequence alignment of B. malayi Glc-3 with 
C. elegans Glc-3 
 
The full length Bma-GLC-3 DNA sequence 
consists of 1461 nucleotides and encodes a 
protein that is 486 amino acids long. This 
protein has the characteristic features of a 
Cys loop ligand - gated ion channel (LGIC). 
These include: the Cys loop motif comprised 
of two disulphide bond forming cysteines in 
the N-terminal extracellular region that are 
separated by 13 amino acid residues and is 
involved in receptor assembly and channel 
gating; four membrane spanning regions 
(TM1 - TM4) which allow for passage of ions 
across the membrane; an intracellular domain 
with a role in channel conductance and 
receptor modulation; ligand binding loops A 
– F. Also present is an additional loop ‘G’ and 
a PAR motif at the very start of the TM2 
region which are characteristic of ligand - 
gated anion channels (Green and 
Wanamaker, 1997; Grutter et al., 2005; 
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Wolstenholme, 2012). (Fig. 1). Alignment of 
the amino acid sequence of Bma-GLC-3 
(WormBase ID: BM:BM8050 with the C. 
elegans GLC-3 sequence (WormBase ID: 
WP:CE28159) using the online EMBL - EBI 
Clustal Omega Multiple Sequence 
Alignment Tool showed a high degree of 
conservation, with 67.53% identity and 76% 
similarity. 
 
 
 
Figure 1. Amino acid sequence alignment of B. 
malayi GLC-3 with C. elegans GLC-3 using the 
EMBL-EBI Clustal O (1.2.4) Multiple Sequence 
Alignment online tool. Percent identity = 67.53%. 
Percent similarity = 76%  Color code: Yellow = ligand 
binding loops A - ‘G’; Green = Cys loop characteristic 
of the Cys loop ligand-gated ion channel superfamily; 
Purple = transmembrane regions 1 - 4 as predicted 
using TMHMM Server v. 2.0; Bold Line = PAR motif 
characteristic of ligand-gated anion channels; 
Residues which make contact with bound glutamate 
are highlighted in red; Binding loops shown following 
Wolstenholme et al., (2012),  
 
Actions of L-glutamate, ibotenate L-
aspartate, glycine, GABA, AMPA, NMDA, 
kainate and quisqualate 
 
The application of 1 mM L-glutamate and 
ibotenate produced slowly desensitizing 
inward current responses from oocytes 
expressing B. malayi GLC-3. No current 
responses were observed following 
applications of 1 mM L-aspartate, AMPA, 
NMDA, kainate and quisqualate, which are 
analogues of L-glutamate and also vertebrate 
glutamate receptor agonists. Application of 1 
mM glycine and GABA which are agonists 
of the closely related glycine and GABA 
receptors respectively, also did not activate 
the Bma-GLC-3 receptor. The rank order 
potency for agonists was: L-glutamate (100 ± 
0.0., n = 13) > ibotenate (73.4 ± 2.5., n = 6) 
>>> kainate (0.0 ± 0.0., n = 6) = L-
quisqualate (0.0 ± 0.0., n = 6) = L-aspartate 
(0.0 ± 0.0., n = 7) = glycine (0.0 ± 0.0., n = 7) 
= GABA (0.0 ± 0.0., n = 7) = AMPA (0.0 ± 
0.0., n = 7) = NMDA (0.0 ± 0.0., n = 7). 
 
 
Bma-GLC-3      MLLPHYDKSSSIIPLIGFDHFNHFPFLLPILSFALIICEIKASTDTDIINKLLGKGYDWR 60 
Cel-GLC-3      ------------------MSLRSLLNILLIVAFWIVGGNCDASSDTEIIKKLLGKGYDWR 42 
                                   :. :  :* *::* ::  : .**:**:**:********** 
                                       ‘G’                 D 
Bma-GLC-3      VRPPGTNLSITGGHGPVVVAVNMLIRSISKIDDVNMEYSVQLTFRESWVDGRLAFGYPRD 120 
Cel-GLC-3      VRPPGINLTIPGTHGAVIVYVNMLIRSISKIDDVNMEYSVQLTFREEWVDGRLAYGFPGD 102 
               ***** **:* * ** *:* **************************.*******:*:* * 
                                  A                             E 
Bma-GLC-3      NTPDFVILTAGQQIWMPDSFFQNEKHAQRHMIDKPNVLIRVHKDGTILYSVRISLVLSCP 180 
Cel-GLC-3      STPDFLILTAGQQIWMPDSFFQNEKQAHKHDIDKPNVLIRIHRDGRILYSVRISMVLSCP 162 
               .****:*******************:*::* *********:*:** ********:***** 
                 Cys loop         B                    F 
Bma-GLC-3      MHLQYYPMDIQTCLIDLASYAYTTDDIEYVWKSKDPVQLKEGLHSSLPSFQLSNVTTTFC 240 
Cel-GLC-3      MHLQYYPMDVQTCLIDLASYAYTENDIEYRWKKTDPVQLKKGLHSSLPSFELNNVDTTLC 222 
               *********:************* :**** **..******:*********:*.** **:* 
                    C                            TM1                  TM2 
Bma-GLC-3      TSKTNTGTYSCLRTVLELRRQFSYYLLQLYVPSSMLVIVSWVSFWLDRTAIPARVTLGVT 300 
Cel-GLC-3      TSKTNTGTYSCLRTVLELRRQFSYYLLQLYIPSTMLVIVSWVSFWLDRGAVPARVTLGVT 282 
               ******************************:**:************** *:********* 
                                                  TM3 
Bma-GLC-3      TLLTMTTQASGINAKLPPVSYTKAIDVWIGACLTFIFGALLEFACVTYMSSRNHSKNMKR 360 
Cel-GLC-3      TLLTMTTQASGINAKLPPVSYTKAIDVWIGACLTFIFGALLEFAWVTYISSRSFYKRNKN 342 
               ******************************************** ***:***.. *. *. 
 
Bma-GLC-3      NKSTNSLMGRTNQMAATQ---LIIF-------NKNAMECGEIWVRQRNDDSDEENGEQFN 410 
Cel-GLC-3      CSSRNSLLIETKQALIIPNTVVAQFPEHPEEVEMGLAQAPDVWIRQSGNGKTV------S 396 
                .* ***: .*:*        :  *       : .  :. ::*:** .:..        . 
 
Bma-GLC-3      MVNGGNKW-----------R-RIRRNRQMLKDYYRQFRFIGWLRRKFHTTDRAKQADYLS 458 
Cel-GLC-3      RVNGHINHNNDEAAELIIFDAKHKNRRFVWWTNFRNIRLIRWIRNRLNVDDNAKRADLIS 456 
                ***  :              : :..* :    :*::*:* *:*.:::. *.**:** :* 
                          TM4 
Bma-GLC-3      RLIFPALFLIFNCAYWLNYSRYPVSRPT 486 
Cel-GLC-3      RVLFPTLFVCFNFVYWTKYSQYHAPEAK 484 
               *::**:**: ** .** :**:* . . . 
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Figure 2. L - glutamate, ibotenate, kainite, L- 
quisqualate L - aspartate, glycine, GABA, AMPA and 
NMDA agonists pharmacology from oocytes 
expressing B. malayi GLC-3 at concentrations of 1 
mM.  
 
 
Glutamate concentration-response  
 
The concentration-response relationship for 
L-glutamate was examined by applying 
increasing concentrations of L-glutamate 
from 3 M - 1 mM to oocytes expressing 
Bma-GLC-3. We observed the slowly 
desensitizing inward currents following L-
glutamate application to be concentration-
dependent. Such effects were not observed in 
the non-injected control oocytes. The L-
glutamate responses (normalized to 1 mM L-
glutamate) were plotted using nonlinear 
regression and the EC50 was estimated to be 
64.8  4.01 µM and a Hill coefficient (nH) of 
2.56  0.46 µM (Fig. 3).  
 
 
 
 
 
Figure 3. L-glutamate concentration-response 
relationship for B. malayi-GLC-3. 
A) Representative of inward current responses from 
Xenopus oocytes expressing Bma- GLC-3. 
B) Concentration-response plot for L-glutamate. L-
glutamate EC50 = 64.8  4.01 µM  and Hill slope = 
2.56  0.46 µM, n = 5 - 13 
 
 
Current-voltage (I-V) relationships 
 
Recordings from 300 µM L-glutamate 
responses over a range of holding potentials 
(-80 to +20 mV) were analyzed. Thereafter, 
we constructed a current-voltage plot. We 
fitted the data using linear regression. The 
current-voltage relationship revealed a 
reversal potential (Erev) of -35.3  3.2 mV 
indicating the GLC-3 channel is selective for 
chloride ions. The result confirmed that 
GLC-3 is permeable to and selective for 
chloride ions. Hence, GLC-3 is a glutamate-
gated chloride channel.  (Fig. 4). 
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Figure 4. Current-voltage relationship for the 
glutamate-gated currents of B. malayi-GLC-3 with a 
reversal potential (Erev) of -35.3  3.2 mV.  
 
Actions of picrotoxin and fipronil 
 
Picrotoxin (PTX) is a noncompetitive 
antagonist for ligand gated ion channels 
(LGICs), the plant-derived toxin 
(picrotoxinin) acts as a potent inhibitor of 
GABA receptors (Timothy et. al., 2013). 
Similarly, the phyl-pyrazole fipronil (FIP) 
acts by blocking chloride ion channels which 
are regulated by GABA receptors and also 
GluCls. Also, fipronil is a systemic 
insecticide widely used for controlling insect 
pests.  (Simon-Delso et al., 2014; Janer et. al., 
2015). We assessed the potency of PTX and 
FIP on expressed Bma- GLC-3 by testing 
both compounds at 0.3 to 100 µM in order to 
generate inhibition plots. Both PTX and FIP 
showed no significant inhibition at these 
concentrations.  
 
 
 
 
 
 
Figure 5. The effect of non-competitive antagonists, a 
picrotoxin (PTX) and b fipronil (Fip) on 300 µM L-
glutamate responses recorded from GLC-3 homo-
oligomers. For each antagonist PTX and FIP, four 
responses are shown 300 µM L-glutamate (control), 
10 µM, 30 µM and 100 µM L-glutamate in the 
presence of test antagonist, 300 µM L-glutamate 
recovery response after a 2-5 min wash in normal 
saline. Concentration-response curves for the actions 
of each antagonist PTX and FIP, on the L-glutamate 
response of the GLC-3 receptor. 
 
-80 -60 -40 -20 20 40
-200
-100
100
200
Erev
Erev = -35.3 ± 3.2 mV
I 
(n
A
)
V (mV)
Ions Equilibrium 
potential
Na+ +61
K+ -100
Cl- -27
 9 
Actions of Ivermectin on GLC-3 receptor 
 
We measured the effect of ivermectin as a 
direct activator of GLC-3 by calculating the 
inward current induced after 2 minutes 
perfusion at various concentrations. The 
resulting ivermectin dose-response 
relationship reveals an inward ivermectin 
sensitive current with an EC50 of 4.0 nM 
(Figure 6A).  We observed that ivermectin 
inhibited glutamate responses. The inhibitory 
actions of ivermectin (IVM) on GLC-3 
responses to concentrations of 10 µM, 100 
µM and 1000 µM L-glutamate were dose-
dependent. Figure 6B shows the dose-
response relationship for ivermectin 
inhibition of the 1000 µM glutamate response 
with an IC50 of 73 pM (pIC50 = -4.1 ± 11.4). 
 
 
  
Figure 6. (A) Concentration-response curves for the 
actions of ivermectin (IVM) at concentration of 10 
µM, 100 µM and 1000 µM L-glutamate (B) Inhibitory 
effect of 1pM Ivermectin on 1000 µM L-glutamate 
responses. 
 
Discussion 
 
Functional expression of Bma-GLC-3 
 
There have been previous accounts of the 
glutamate gated chloride channel subunit 
(GLC-3) as one of the primary targets of the 
macrocyclic lactone anthelmintics in several 
parasites such as Cyathostomin species 
(Krystyna et al., 2013). Here we report that 
GLC-3 from B. malayi expresses as a 
functional homomeric channel in Xenopus 
oocytes.  
The alignment of B. malayi GLC-3 amino-
acid sequence with that of the soil nematode 
C. elegans GLC-3 present an identity of 
67.53%. These comparative analyses offer a 
complementary approach to extensively 
analyze our parasite of focus (Brugia 
malayi). Our results also show that the 
application of L-glutamate to Bma-GLC-3 
yielded a slowly desensitizing concentration-
dependent inward currents compared to the 
Bma-AVR-14b channel where the inward 
currents desensitize rapidly.  
 
In this present study, we applied L-glutamate 
at concentrations of 3M - 1 mM to Xenopus 
oocytes expressing Bma-GLC-3 to determine 
the concentration-response relationship for 
L-glutamate. The recordings gave rapid 
desensitizing inward currents following L-
glutamate application.  The EC50 and Hill 
coefficient were 64.8  4.01 µM and 2.56  
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0.46 µM respectively. For the agonist 
experiment, the rank order potency for L-
glutamate was 100 ± 0.0., n = 13 and 
ibotenate was 73.4 ± 2.5., n = 6. While, for 
other agonists tested no responses were 
observed. This is similar to a previous report 
by Horoszok et. al. (2001) from C. elegans 
GLC. They reported that L-glutamate and 
ibotenate activated the GLC-3 receptor at 
1mM, but ibotenate produced currents of a 
smaller amplitude and slower onset than L-
glutamate.   
Furthermore, we analyzed the current 
produced by 300 M L-glutamate over a 
voltage range of –80 to +20 mV at glutamate-
gated current of B. malayi-GLC-3. From a 
plot of current (I) against voltage (V), the 
current-voltage (I-V) relationship was 
observed and a reversal potential (Erev) of -
35.3  3.2 mV was calculated by linear 
regression. This result shows that GLC-3 
channel is selective for chloride ions. 
 
 
Bma-GLC-3 is insensitive to fipronil and 
picrotoxin 
 
Fipronil and PTX are non-competitive 
antagonists of ionotropic receptors 
containing chloride channels. The 
interactions of these non-competitive 
antagonists with ligand-gated chloride 
channels has revealed some interesting 
pharmacology of the Bma-GLC-3 receptor. 
In our experiments, we observed that the 
GLC-3 channels from Brugia malayi are 
insensitive to fipronil and picrotoxin at 
concentrations up to 100 µM. In contrast, 
previous experiments on Cel-GLC-3 
revealed the channel to be inhibited by 
fipronil with an IC50 of 11.5 ± 0.11 µM but 
picrotoxinin-insensitive (Horoszok et. al., 
2001).  
 
Ivermectin effects on GLC-3 receptor 
 
Ivermectin is a member of the macrocyclic 
lactones anthelmintic class. GluCls are 
targets for avermectin/milbemycin (A/M) 
family of anthelmintics. Ivermectin binds to 
glutamate-gated chloride channels (GluCls) 
in the membranes of invertebrate nerve and 
muscle cells, causing increased permeability 
to chloride ions, enhancing inhibitory 
neurotransmission, resulting in cellular 
hyper-polarization followed by paralysis and 
death. 
Our results using ivermectin showed it 
directly active Bma-GLC-3 with an EC50 of 
3.6 nM (pEC50 = -2.4 ± 0.4). Further analysis 
shows an inhibitory effect of Ivermectin on 
1mM glutamate responses, IC50 of 73 pM 
(pIC50 = -4.1 ± 11.4). This is in stark contrast 
to the previously reported positive allosteric 
(PAM) effects of ivermectin on many 
invertebrate GluCls. 
 
Studies relating to Ivermectin have shown 
that ivermectin has a limited action against 
adult filarial worms. Preliminary study using 
the worminator motility technique to show 
how Adult Brugia malayi move in the 
presence of Ivermectin also confirmed the 
poor action of Ivermectin on the adult filarial 
worm. However, IVM is more effective on 
microfilarae of Brugia malayi. A previous 
report by Yovany et. al., (2010) revealed that 
IVM treatment for filarial infections is 
characterized by an initial dramatic drop in 
the levels of circulating microfilariae, 
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followed by long-term suppression of their 
production. 
 
Conclusion  
 
The objective of this study was to examine 
the pharmacological properties of GLC-3 
from adult B. malayi expressed in Xenopus 
oocytes. Our results show the complex mode 
of action of IVM. Ivermectin acts as a direct 
activator of Bma-GLC-3, similar to its effects 
on Cel-GLC-3 (Horoszok et. al., 2001).  
Interestingly, ivermectin also acts as an 
inhibitor of Bma-GLC-3 glutamate 
responses, this is the opposite of its PAM 
effects on GLCs from other invertebrate 
species (Horoszok et. al., 2001).  
It can be suggested that the GLC-3 channel 
from filarial adults may have a reduced 
sensitivity to ivermectin compared to other 
GluCls receptors from nematode species 
where the drug is effective. GLC-3 might co-
assemble with one or more of the other GluCl 
subunits to form a component of the parasite 
GluCl receptor. Our results enhance our 
overall understanding of the glutamate-gated 
chloride channels in filarial nematodes.  
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